Zobrazeno 1 - 10
of 32
pro vyhledávání: '"William Slichenmyer"'
Publikováno v:
Clinical Pharmacology in Drug Development. 4:137-142
The vascular endothelial growth factor (VEGF) pathway is associated with the promotion of endothelial cell proliferation, migration, and survival necessary for angiogenesis. VEGF and its three receptor isoforms are often overexpressed in many human s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2603ba66682825b006423bcfc5ba79b4
https://doi.org/10.1002/cpdd.145
https://doi.org/10.1002/cpdd.145
Publikováno v:
Clinical Pharmacology in Drug Development. 3:158-162
Tivozanib hydrochloride (tivozanib) is a potent, selective tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1, 2, and 3, with a long half-life. This Phase I study evaluated the effect of food on tivozanib pharmacokinetics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4ace04e2d5e962483c99f9eba0d3997
https://doi.org/10.1002/cpdd.76
https://doi.org/10.1002/cpdd.76
Autor:
Madhu Sanga, Claudine S. Oelke, Strahs Andrew, Monette M. Cotreau, William Slichenmyer, Lindsey Jacobson, Christine Hale, Dennis L. Vargo, Robert G. Kochan
Publikováno v:
Clinical pharmacology in drug development. 1(3)
Objective To evaluate the absorption, metabolism, and excretion of tivozanib, a new investigational drug for renal cell carcinoma and solid malignancies. Methods Eight healthy male participants received a single 1.5-mg (˜160 μCi) dose of oral [(14)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11cf6a8d00cb3cba86609fd92d002aec
https://pubmed.ncbi.nlm.nih.gov/27121337
https://pubmed.ncbi.nlm.nih.gov/27121337
Autor:
Monette M, Cotreau, Nicholas M, Siebers, James, Miller, Andrew L, Strahs, William, Slichenmyer
Publikováno v:
Clinical pharmacology in drug development. 4(2)
The vascular endothelial growth factor (VEGF) pathway is associated with the promotion of endothelial cell proliferation, migration, and survival necessary for angiogenesis. VEGF and its three receptor isoforms are often overexpressed in many human s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::582135ab93f83365229cacd5e0002a5d
https://pubmed.ncbi.nlm.nih.gov/27128217
https://pubmed.ncbi.nlm.nih.gov/27128217
Autor:
Ronald B. Natale, Peter F. Lenehan, Erwin Jeong, William Slichenmyer, Liang Chen, Mark Meyer, Barbara Bolinger
Publikováno v:
American Journal of Clinical Oncology: Cancer Clinical Trials. 24:167-171
Potential interaction between suramin and warfarin was evaluated when coadministered to patients with cancer. Thirteen men with advanced hormone-refractory prostate cancer were initially stabilized with warfarin to a prothrombin time (PT) of 2 +/- 0.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ed47081c6b3c76321797a82488e5a89
https://doi.org/10.1097/00000421-200104000-00014
https://doi.org/10.1097/00000421-200104000-00014
Autor:
Raymond C. Bergan, William Slichenmyer, Stephen K Carter, Michael Meyers, Doyle H Waggle, Ivan Horak
Publikováno v:
Urology. 57:77-80
Cell growth and differentiation are processes intimately associated with carcinogenesis and regulated by tyrosine kinases and other signaling proteins. Identification of drugs that target signaling molecules is hampered by both the large number of ta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed6e42336991a2fbdc59b3853fbc6ebd
https://doi.org/10.1016/s0090-4295(00)00946-8
https://doi.org/10.1016/s0090-4295(00)00946-8
Autor:
Liang Chen, Peter F. Lenehan, William Slichenmyer, Alex McMillan, Mario A. Eisenberger, Mark Meyer, Eric J. Small
Publikováno v:
Journal of Clinical Oncology. 19:1304-1311
PURPOSE: Validated end points are lacking for clinical trials in hormone-refractory prostate cancer (HRPC). Controversy remains regarding the utility of a posttreatment decline of prostate-specific antigen (PSA). The purpose of this study was to dete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::580880928fa758a3d584be9b3798baff
https://doi.org/10.1200/jco.2001.19.5.1304
https://doi.org/10.1200/jco.2001.19.5.1304
Autor:
Andrew Strahs, Mayer Fishman, Ralph J. Hauke, Sandy Srinivas, William Slichenmyer, Monette M. Cotreau, Brooke Esteves, Fairooz F. Kabbinavar, P. Bhargava, Robert J. Amato
Background Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, with a long half-life. Tivozanib has demonstrated clinical activity and acceptable tolerability in renal ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e58f3d34ad3610158b0bab2ceacd1d9
https://europepmc.org/articles/PMC4666006/
https://europepmc.org/articles/PMC4666006/
Autor:
Monette M, Cotreau, Lisa, Massmanian, Andrew L, Strahs, William, Slichenmyer, Dennis L, Vargo
Publikováno v:
Clinical pharmacology in drug development. 3(2)
Tivozanib hydrochloride (tivozanib) is a potent, selective tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1, 2, and 3, with a long half-life. This Phase I study evaluated the effect of food on tivozanib pharmacokinetics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::30def528ff5f2b5dd0df4c669bf55f0b
https://pubmed.ncbi.nlm.nih.gov/27128461
https://pubmed.ncbi.nlm.nih.gov/27128461
Autor:
Seamus O'Reilly, Eric K. Rowinsky, Arlene A. Forastiere, Ross C. Donehower, Louise B. Grochow, S E Sartorius, William Slichenmyer, David S. Ettinger, Tian Ling Chen
Publikováno v:
Journal of Clinical Oncology. 14:3062-3073
PURPOSE To determine the toxicities, pharmacokinetics, and recommended doses of the topoisomerase I inhibitor, topotecan, in patients with varying degrees of renal excretory dysfunction. PATIENTS AND METHODS Fourteen patients with normal renal functi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a0a90fa65aca650b62a9032828dbe6a4
https://doi.org/10.1200/jco.1996.14.12.3062
https://doi.org/10.1200/jco.1996.14.12.3062